Par Pharmaceutical: Par launches generic Cuvposa
The product is indicated to reduce chronic severe drooling in children aged 3 to 16 years old with neurologic conditions that cause abnormal drooling.
Read full article »
CEO
Par Pharmaceutical develops, manufactures and markets generic and branded specialty pharmaceutical products in the United States.
Read more